Friday, January 04, 2013

FDA issues warning over Hepatitis C drug

The Food and Drug Administration is warning patients receiving treatment for hepatitis C with a triple drug regimen using Incevik, or telepriver, to be aware of a potentially dangerous, even fatal skin reaction.
The FDA on Wednesday announced it has altered Incevik’s label to include stronger warnings after some patients died from complications after developing a serious rash while taking Incevik along with two other medications for hepatitis C.
More than 2,700 active duty service members were diagnosed with chronic hepatitis C between 2000 and 2010, according to Pentagon data.
The Veterans Health Administration system has 170,000 patients with chronic hepatitis C, and more than 4,800 VA patients are receiving some kind of combination drug therapy for Hepatitis C.